Supplementary Table 3.
Basic Characteristics of Vaccinated Individuals With and Without IBD and Unvaccinated Individuals With and Without IBD in Matched Cohort
| Not vaccinated |
Vaccinated |
Non-IBD (N = 4946) | P value | SMD | ||||
|---|---|---|---|---|---|---|---|---|
| IBD (N = 4694) | Non-IBD (N = 4694) | P value | SMD | IBD (N = 4946) | ||||
| Age (y) | 52 ± 24 | 52 ± 24 | .973 | 0.002 | 51 ± 16 | 51 ± 16) | .979 | 0.001 |
| Age group (y) | 1 | <0.001 | 1 | <0.001 | ||||
| <18 | 267 (5.7%) | 267 (5.7%) | 20 (0.4%) | 20 (0.4%) | ||||
| 18–39 | 1407 (30%) | 1407 (30%) | 1288 (26%) | 1288 (26%) | ||||
| 40–49 | 816 (17%) | 816 (17%) | 1015 (21%) | 1015 (21%) | ||||
| 50–59 | 603 (13%) | 603 (13%) | 1032 (21%) | 1032 (21%) | ||||
| 60–69 | 411 (8.8%) | 411 (8.8%) | 823 (17%) | 823 (17%) | ||||
| 70–79 | 416 (8.9%) | 416 (8.9%) | 627 (13%) | 627 (13%) | ||||
| 80+ | 774 (17%) | 774 (17%) | 141 (2.9%) | 141 (2.9%) | ||||
| Sex, male | 2414 (51%) | 2414 (51%) | 1 | <0.001 | 2412 (49%) | 2412 (49%) | 1 | <0.001 |
| Disease duration (y) | 11 (5.7–17) | — | 12 (1–24) | — | ||||
| Weeks from second vaccine | 22 (4–22) | 22 (4–22) | 1 | <0.001 | ||||
| BMI category | <.001 | 0.215 | .008 | 0.069 | ||||
| Overweight (25–29.9 kg/m2) | 163 (3.5%) | 32 (0.7%) | 69 (1.4%) | 64 (1.3%) | ||||
| Obese (30–39.99 kg/m2) | 192 (4.1%) | 137 (2.9%) | 320 (6.5%) | 340 (6.9%) | ||||
| Severe obesity (>40 kg/m2) | 67 (1.4%) | 99 (2.1%) | 143 (2.9%) | 203 (4.1%) | ||||
| Pregnancy | 122 (2.6%) | 109 (2.3%) | .424 | 0.018 | 75 (1.5%) | 59 (1.2%) | .069 | 0.039 |
| Treatment over last year | ||||||||
| Anti-TNF | 319 (6.8%) | 0 (0%) | <.001 | 0.382 | 42 (0.8%) | 0 (0%) | <.001 | 0.467 |
| Corticosteroid | 162 (3.5%) | 0 (0%) | <.001 | 0.267 | 10 (0.2%) | 0 (0%) | <.001 | 0.293 |
| Immunomodulator | 178 (3.8%) | 0 (0%) | <.001 | 0.281 | 13 (0.3%) | 0 (0%) | <.001 | 0.356 |
| Mesalamine | 537 (11%) | 0 (0%) | <.001 | 0.508 | 90 (1.8%) | 0 (0%) | <.001 | 0.91 |
| Vedolizumab | 86 (1.8%) | 0 (0%) | <.001 | 0.193 | 11 (0.2%) | 0 (0%) | <.001 | 0.28 |
| Ustekinumab | 55 (1.2%) | 0 (0%) | <.001 | 0.154 | 8 (0.2%) | 0 (0%) | <.001 | 0.2 |
| Tofacitinib | 10 (0.2%) | 0 (0%) | .004 | 0.065 | 2 (0.0%) | 0 (0%) | <.001 | 0.11 |
| IBD surgery ever | 705 (15%) | 0 (0%) | <.001 | 0.595 | 668 (14%) | 0 (0%) | <.001 | 1.33 |
| IBD hospitalization ever | 2540 (54%) | 0 (0%) | <.001 | 1.536 | 2329 (47%) | 0 (0%) | <.001 | 0.56 |
| Corticosteroids use ever | 2586 (55%) | 0 (0%) | <.001 | 1.566 | 2722 (55%) | 0 (0%) | <.001 | 1.57 |
| Preexisting conditions scorea | <.001 | 0.283 | .011 | 0.073 | ||||
| 0 | 1987 (42%) | 2619 (56%) | 2001 (41%) | 2099 (42%) | ||||
| 1 | 1106 (24%) | 915 (20%) | 1352 (27%) | 1388 (28%) | ||||
| 2 | 543 (12%) | 433 (9.2%) | 736 (15%) | 696 (14%) | ||||
| 3 | 344 (7.3%) | 278 (5.9%) | 404 (8.2%) | 396 (8.0%) | ||||
| 4+ | 714 (15%) | 449 (10%) | 453 (9.2%) | 367 (7.4%) | ||||
| Preexisting conditions | ||||||||
| Cancer | 247 (5.3%) | 197 (4.2%) | .017 | 0.05 | 282 (5.7%) | 236 (4.8%) | .042 | 0.042 |
| Chronic kidney disease | 376 (8.0%) | 234 (5.0%) | <.001 | 0.123 | 228 (4.6%) | 145 (2.9%) | <.001 | 0.088 |
| Chronic obstructive pulmonary disease | 358 (7.6%) | 181 (3.9%) | <.001 | 0.163 | 220 (4.4%) | 180 (3.6%) | .047 | 0.041 |
| Heart conditions | 805 (17%) | 574 (12%) | <.001 | 0.139 | 520 (10.5%) | 509 (10.3%) | .742 | 0.007 |
| Organ transplant | 13 (0.3%) | 4 (0.1%) | .052 | 0.045 | 8 (0.2%) | 5 (0.1%) | .579 | 0.017 |
| Sickle cell | 0 (0%) | 0 (0%) | 1 | <0.001 | 0 (0%) | 0 (0%) | 1 | <0.001 |
| Type II diabetes | 665 (14%) | 597 (13%) | <.001 | 0.244 | 703 (14%) | 732 (15%) | .424 | 0.017 |
| Asthma | 994 (21%) | 571 (12%) | <.001 | 0.306 | 892 (18%) | 820 (17%) | .059 | 0.038 |
| Cerebrovascular disease | 500 (11%) | 320 (6.8%) | <.001 | 0.136 | 390 (7.9%) | 346 (7.0%) | .099 | 0.034 |
| Other respiratory disease | 99 (2.1%) | 23 (0.5%) | <.001 | 0.143 | 80 (1.6%) | 45 (0.9%) | .002 | 0.063 |
| Hypertension | 1339 (29%) | 1124 (24%) | <.001 | 0.104 | 1380 (28%) | 1462 (30%) | .072 | 0.037 |
| Immunocompromised state | 19 (0.4%) | 14 (0.3%) | .485 | 0.018 | 15 (0.3%) | 13 (0.3%) | .85 | 0.008 |
| Type I diabetes | 107 (2.3%) | 82 (1.7%) | .078 | 0.038 | 107 (2.2%) | 89 (1.8%) | .22 | 0.026 |
| Liver disease | 492 (11%) | 308 (6.6%) | <.001 | 0.141 | 726 (15%) | 603 (12%) | <.001 | 0.073 |
| Thalassemia | 47 (1.0%) | 25 (0.5%) | .013 | 0.054 | 42 (0.8%) | 38 (0.8%) | .736 | 0.009 |
NOTE. Count (%), mean ± standard deviation, or medians (IQR) are presented as appropriate.
BMI, body mass index.
a
Count of total number of preexisting conditions defined by the Centers for Disease Control as risk factors (Appendix 1).